This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neuromuscular diseases  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Costanza Lamperti, MD; Ali B. Naini, PhD; Valeria Lucchini, MD; Alessandro Prelle, MD; Nereo Bresolin, MD; Maurizio Moggio, MD; Monica Sciacco, MD; Petra Kaufmann, MD; Salvatore DiMauro, MD

Arch Neurol. 2005;62:1709-1712.

Background  Statin drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the cholesterol biosynthetic pathway. Use of statin drugs has been associated with a variety of skeletal muscle–related complaints. Coenzyme Q₁₀ (CoQ₁₀), a component of the mitochondrial respiratory chain, is also synthesized from mevalonate, and decreased muscle CoQ₁₀ concentration may have a role in the pathogenesis of statin drug–related myopathy.

Objectives  To measure the CoQ₁₀ concentration and respiratory chain enzyme activities in muscle biopsy specimens from 18 patients with statin drug–related myopathy and to look for evidence of apoptosis using the TUNEL (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling) assay.

Design  An open-labeled study of CoQ₁₀ concentration in muscle from patients with increased serum creatine kinase concentrations while receiving standard statin drug therapy.

Setting  Neuromuscular centers at 2 academic tertiary care hospitals.

Results  Muscle structure was essentially normal in 14 patients and showed evidence of mitochondrial dysfunction and nonspecific myopathic changes in 2 patients each. Muscle CoQ₁₀ concentration was not statistically different between patients and control subjects, but it was more than 2 SDs below the normal mean in 3 patients and more than 1 SD below normal in 7 patients. There was no TUNEL positivity in any patients.

Conclusion  These data suggest that statin drug–related myopathy is associated with a mild decrease in muscle CoQ₁₀ concentration, which does not cause histochemical or biochemical evidence of mitochondrial myopathy or morphologic evidence of apoptosis in most patients.

Author Affiliations: Centro Dino Ferrari, Dipartimento di Scienze Neurologiche, Unita’ Operativa, Neurologia, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, University of Milan, Milan, Italy (Drs Lamperti, Lucchini, Prelle, Bresolin, Moggio, and Sciacco); and Department of Neurology, Columbia University Medical Center, New York, NY (Drs Naini, Kaufmann, and DiMauro).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review
Marcoff and Thompson
J Am Coll Cardiol 2007;49:2231-2237.
ABSTRACT | FULL TEXT  

Which statin, what dose?
DTB 2007;45:33-37.
ABSTRACT | FULL TEXT  

Considerations for Supplementing with Coenzyme Q10 During Statin Therapy
Levy and Kohlhaas
The Annals of Pharmacotherapy 2006;40:290-294.
ABSTRACT | FULL TEXT